Cortisol, 11β-hydroxysteroid dehydrogenases, and hypertension

Seminars in Vascular Medicine

Volumn 4, Issue 2, 2004, Pages 121-128

  Van Uum, Stan H M ^a   Lenders, Jacques W M ^b   Hermus, Ad R M M ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

11 hydroxysteroid dehydrogenases; Cortisol; Hypertension; Licorice

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CORTICOSTERONE; CORTICOTROPIN; DEOXYCORTICOSTERONE; DEXAMETHASONE; HYDROCORTISONE; MINERALOCORTICOID RECEPTOR; SODIUM CHLORIDE;

BLOOD PRESSURE; BLOOD VESSEL TONE; CENTRAL NERVOUS SYSTEM; CHRONIC KIDNEY FAILURE; CUSHING SYNDROME; DIET; ENZYME ACTIVITY; ENZYME SUBUNIT; GENE MUTATION; GLYCYRRHIZA; HORMONE METABOLISM; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; HYPERTENSION; HYPOKALEMIA; KIDNEY; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN FUNCTION; REVIEW; TISSUE DISTRIBUTION; ANIMAL; BLOOD; FETUS; PHYSIOLOGY; PLACENTA; RENOVASCULAR HYPERTENSION; SECRETION;

11-BETA-HYDROXYSTEROID DEHYDROGENASES; ANIMALS; BLOOD PRESSURE; CUSHING SYNDROME; FETUS; GLYCYRRHIZA; HUMANS; HYDROCORTISONE; HYPERTENSION; HYPERTENSION, RENAL; KIDNEY; KIDNEY FAILURE, CHRONIC; PLACENTA; RECEPTORS, MINERALOCORTICOID;

EID: 7244247137     PISSN: 15289648     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-835369     Document Type: Review

References (70)

1. Danese RD, Aron DC. Cushing's syndrome and hypertension. Endocrinol Metab Clin North Am 1994;23:299-324
2. Fallo F, Paoletta A, Tona F, et al. Response of hypertension to conventional antihypertensive treatment and/or steroidogenesis inhibitors in Cushing's syndrome. J Intern Med 1993;234:595-598
3. Connell JM, Whitworth JA, Davies DL, et al. Effects of ACTH and cortisol administration on blood pressure, electrolyte metabolism, atrial natriuretic peptide and renal function in normal man. J Hypertens 1987;5:425-433
4. Vermeulen A, van der Straeten M. Adrenal cortical function in benign essential hypertension. J Clin Endocrinol Metab 1963;23:574-578
5. Filipovsky J, Ducimetiere P, Eschwege E, et al. The relationship of blood pressure with glucose, insulin, heart rate, free fatty acids and plasma cortisol levels according to degree of obesity in middle-aged men. J Hypertens 1996;14:229-235
6. Whitworth JA, Gordon D, McLachlan Troup N, et al. Dexamethasone suppression in essential hypertension: effects on cortisol and blood pressure. Clin Exp Hypertens A 1989;11:323-335
7. Lakshmi V, Monder C. Evidence for independent 11-oxidase and 11-reductase activities of 11 beta-hydroxysteroid dehydrogenase: enzyme latency, phase transitions, and lipid requirements. Endocrinology 1985;116:552-560
8. Monder C, White PC. 11 beta-hydroxysteroid dehydrogenase. Vitam Horm 1993;47:187-271
9. Walker BR, Campbell JC, Williams BC, et al. Tissue-specific distribution of the NAD(+)-dependent isoform of 11 beta-hydroxysteroid dehydrogenase. Endocrinology 1992;131:970-972
10. Whorwood CB, Mason JI, Ricketts ML, et al. Detection of human 11 beta-hydroxysteroid dehydrogenase isoforms using reverse-transcriptase- polymerase chain reaction and localization of the type 2 isoform to renal collecting ducts. Mol Cell Endocrinol 1995;110:R7-12
11. Stewart PM, Murry BA, Mason JI. Human kidney 11 beta-hydroxysteroid dehydrogenase is a high affinity nicotinamide adenine dinucleotide-dependent enzyme and differs from the cloned type I isoform. J Clin Endocrinol Metab 1994;79:480-484
12. Agarwal AK, Tusie-Luna MT, Monder C, et al. Expression of 11 beta-hydroxysteroid dehydrogenase using recombinant vaccinia virus. Mol Endocrinol 1990;4:1827-1832
13. Brown RW, Chapman KE, Kotelevtsev Y, et al. Cloning and production of antisera to human placental 11beta-hydroxysteroid dehydrogenase type 2. Biochem J 1996;313:1007-1017
14. Smith RE, Maguire JA, Stein Oakley AN, et al. Localization of 11 beta-hydroxysteroid dehydrogenase type II in human epithelial tissues. J Clin Endocrinol Metab 1996;81:3244-3248
15. Arriza JL, Weinberger C, Cerelli G, et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987;237:268-275
16. Palermo M, Shackleton CH, Mantero F, et al. Urinary free cortisone and the assessment of 11 beta- hydroxysteroid dehydrogenase activity in man. Clin Endocrinol (Oxf) 1996; 45:605-611
17. Ulick S, Levine LS, Gunczler P, et al. A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol. J Clin Endocrinol Metab 1979;49:757-764
18. New MI, Levine LS, Biglieri EG, et al. Evidence for an unidentified steroid in a child with apparent mineralocorticoid hypertension. J Clin Endocrinol Metab 1977;44:924-933
19. Quinkler M, Stewart PM. Hypertension and the cortisol-cortisone shuttle. J Clin Endocrinol Metab 2003;88:2384-2392
20. Milford DV, Shackleton CH, Stewart PM. Mineralocorticoid hypertension and congenital deficiency of 11 beta-hydroxysteroid dehydrogenase in a family with the syndrome of 'apparent' mineralocorticoid excess. Clin Endocrinol (Oxf) 1995;43:241-246
21. Stewart PM, Corrie JE, Shackleton CH, et al. Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle. J Clin Invest 1988;82:340-349
22. Stewart PM, Wallace AM, Valentino R, et al. Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet 1987;2:821-824
23. MacKenzie MA, Hoefnagels WHL, Jansen RWMM, et al. The influence of glycyrrhetinic acid on plasma cortisol and cortisone in healthy young volunteers. J Clin Endocrinol Metab 1990;70:1637-1643
24. Stormer FC, Reistad R, Alexander J. Glycyrrhizic acid in liquorice - evaluation of health hazard. Food Chem Toxicol 1993;31:303-312
25. Walker BR, Campbell JC, Fraser R, et al. Mineralocorticoid excess and inhibition of 11 beta-hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome. Clin Endocrinol 1992;37:483-492
26. Diederich S, Quinkler M, Miller K, et al. Human kidney 11 beta-hydroxysteroid dehydrogenase: regulation by adrenocorticotropin? Eur J Endocrinol 1996;134:301-307
27. van Uum SH, Houben AJ, Hermus AR, et al. Acute intrarenal administration of cortisol has no effect on renal blood flow in hypertensive individuals. J Hypertens 2002;20:2275-2283
28. Whitworth JA, Stewart PM, Burt D, et al. The kidney is the major site of cortisone production in man. Clin Endocrinol (Oxf) 1989;31:355-361
29. Riddle MC, McDaniel PA. Renal 11 beta-hydroxysteroid dehydrogenase activity is enhanced by ramipril and captopril. J Clin Endocrinol Metab 1994;78:830-834
30. Burnier M, Roch-Ramel F, Brunner HR. Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int 1996;49:1787-1790
31. Kerstens MN, Buter H, Navis GJ, et al. 11beta-hydroxysteroid dehydrogenase activity in proteinuric patients and the effect of angiotensin-II receptor blockade. Eur J Clin Invest 2002;32:513-518
32. Soro A, Ingram MC, Tonolo G, et al. Evidence of coexisting changes in 11 beta-hydroxysteroid dehydrogenase and 5 beta-reductase activity in subjects with untreated essential hypertension. Hypertension 1995;25:67-70
33. Takeda Y, Miyamori I, Iki K, et al. Endogenous renal 11 beta-hydroxysteroid dehydrogenase inhibitory factors in patients with low-renin essential hypertension. Hypertension 1996;27:197-201
34. Iki K, Miyamori I, Hatakeyama H, et al. The activities of 5 beta-reductase and 11 beta-hydroxysteroid dehydrogenase in essential hypertension. Steroids 1994;59:656-660
35. van Uum SH, Walker BR, Hermus AR, et al. Effect of glycyrrhetinic acid on 11 beta-hydroxysteroid dehydrogenase activity in normotensive and hypertensive subjects. Clin Sci (Lond) 2002;102:203-211
36. Walker BR, Stewart PM, Shackleton CH, et al. Deficient inactivation of cortisol by 11 beta-hydroxysteroid dehydrogenase in essential hypertension. Clin Endocrinol 1993;39:221-227
37. Walker BR, Phillips DI, Noon JP, et al. Increased glucocorticoid activity in men with cardiovascular risk factors. Hypertension 1998;31:891-895
38. Sigurjonsdottir HA, Franzson L, Manhem K, et al. Liquorice-induced rise in blood pressure: a linear dose-response relationship. J Hum Hypertens 2001;15:549-552
39. Sigurjonsdottir HA, Manhem K, Axelson M, et al. Subjects with essential hypertension are more sensitive to the inhibition of 11 beta-HSD by liquorice. J Hum Hypertens 2003;17:125-131
40. Lovati E, Ferrari P, Dick B, et al. Molecular basis of human salt sensitivity: the role of the 11beta-hydroxysteroid dehydrogenase type 2. J Clin Endocrinol Metab 1999;84:3745-3749
41. Ferrari P, Sansonnens A, Dick B, et al. In vivo 11beta-HSD-2 activity: variability, salt-sensitivity, and effect of licorice. Hypertension 2001;38:1330-1336
42. Kerstens MN, van der Kleij FG, Boonstra AH, et al. Salt loading affects cortisol metabolism in normotensive subjects: relationships with salt sensitivity. J Clin Endocrinol Metab 2003;88:4180-4185
43. Kornel L, Ramsay C, Kanamarlapudi N, et al. Evidence for the presence in arterial walls of intracellular- molecular mechanism for action of mineralocorticoids. Clin Exp Hypertens A 1982;4:1561-1582
44. Ullian ME. The role of corticosteroids in the regulation of vascular tone. Cardiovasc Res 1999;41:55-64
45. Kalsner S. Mechanism of hydrocortisone potentiation of responses to epinephrine and norepinephrine in rabbit aorta. Circ Res 1969;24:383-395
46. Besse JC, Bass AD. Potentiation by hydrocortisone of responses to catecholamines in vascular smooth muscle. J Pharmacol Exp Ther 1966;154:224-238
47. Beilin LJ, Wade DN, Honour AJ, et al. Vascular hyperreactivity with sodium loading and with desoxycorticosterone induced hypertension in the rat. Clin Sci 1970;39:793-810
48. Angelo Khattar MM, Thulesius O. Vascular effects of glucocorticosteroids, with special reference to budesonide. Gen Pharmacol 1983;14:125-127
49. Berecek KH, Bohr DF. Whole body vascular reactivity during the development of deoxycorticosterone acetate hypertension in the pig. Circ Res 1978;42:764-771
50. Grunfeld JP, Eloy L. Glucocorticoids modulate vascular reactivity in the rat. Hypertension 1987;10:608-618
51. Sudhir K, Jennings GL, Esler MD, et al. Hydrocortisone-induced hypertension in humans: pressor responsiveness and sympathetic function. Hypertension 1989;13:416-421
52. Mangos GJ, Walker BR, Kelly JJ, et al. Cortisol inhibits cholinergic vasodilation in the human forearm. Am J Hypertens 2000;13:1155-1160
53. Pirpiris M, Sudhir K, Yeung S, et al. Pressor responsiveness in corticosteroid-induced hypertension in humans. Hypertension 1992;19:567-574
54. Walker BR, Yau JL, Brett LP, et al. 11 beta-hydroxysteroid dehydrogenase in vascular smooth muscle and heart: implications for cardiovascular responses to glucocorticoids. Endocrinology 1991;129:3305-3312
55. Walker BR, Connacher AA, Webb DJ, et al. Glucocorticoids and blood pressure: a role for the cortisol/cortisone shuttle in the control of vascular tone in man. Clin Sci Colch 1992;83:171-178
56. Jamieson PM, Chapman KE, Edwards CR, et al. 11 beta-hydroxysteroid dehydrogenase is an exclusive 11 beta-reductase in primary cultures of rat hepatocytes: effect of physicochemical and hormonal manipulations. Endocrinology 1995;136:4754-4761
57. Seckl JR, Walker BR. Minireview: 11beta-hydroxysteroid dehydrogenase type 1- a tissue-specific amplifier of glucocorticoid action. Endocrinology 2001;142:1371-1376
58. Smith RE, Little PJ, Maguire JA, et al. Vascular localization of the 11 beta-hydroxysteroid dehydrogenase type II enzyme. Clin Exp Pharmacol Physiol 1996;23:549-551
59. Hadoke PW, Christy C, Kotelevtsev YV, et al. Endothelial cell dysfunction in mice after transgenic knockout of type 2, but not type 1, 11beta-hydroxysteroid dehydrogenase. Circulation 2001;104:2832-2837
60. Christy C, Hadoke PW, Paterson JM, et al. 11beta-hydroxysteroid dehydrogenase type 2 in mouse aorta: localization and influence on response to glucocorticoids. Hypertension 2003;42:580-587
61. Reul JM, de Kloet ER. Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation. Endocrinology 1985;117:2505-2511
62. Roland BL, Li KX, Funder JW. Hybridization histochemical localization of 11 beta-hydroxysteroid dehydrogenase type 2 in rat brain. Endocrinology 1995;136:4697-4700
63. Gomez-Sanchez EP, Fort CM, Gomez-Sanchez CE. Intracerebroventricular infusion of RU28318 blocks aldosterone-salt hypertension. Am J Physiol 1990;258:E482-E484
64. Barker DJ, Bull AR, Osmond C, et al. Fetal and placental size and risk of hypertension in adult life. BMJ 1990;301:259-262
65. Huxley RR, Shiell AW, Law CM. The role of size at birth and postnatal catch-up growth in determining systolic blood pressure: a systematic review of the literature. J Hypertens 2000;18:815-831
66. Reinisch JM, Simon NG, Karow WG, et al. Prenatal exposure to prednisone in humans and animals retards intrauterine growth. Science 1978;202:436-438
67. Benediktsson R, Lindsay RS, Noble J, et al. Glucocorticoid exposure in utero: new model for adult hypertension. Lancet 1993;341:339-341
68. Lindsay RS, Lindsay RM, Waddell BJ, et al. Prenatal glucocorticoid exposure leads to offspring hyperglycaemia in the rat: studies with the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone. Diabetologia 1996;39:1299-1305
69. Stewart PM, Rogerson FM, Mason JI. Type 2 11 beta-hydroxysteroid dehydrogenase messenger ribonudeic acid and activity in human placenta and fetal membranes: its relationship to birth weight and putative role in fetal adrenal steroidogenesis. J Clin Endocrinol Metab 1995;80:885-890
70. Strandberg TE, Jarvenpaa AL, Vanhanen H, et al. Birth outcome in relation to licorice consumption during pregnancy. Am J Epidemiol 2001;153:1085-1088